NEW YORK (GenomeWeb) – Gyros Protein Technologies has signed a distribution agreement with Euro Diagnostica giving GPT's customers in Europe and North America direct access to Euro Diagnostica's iLite assay-ready cell lines.
The iLite technology is based upon a reporter gene assay format that is modified and adapted for applications through the whole drug development cycle, as well as for monitoring of biological drugs.
The assays are highly complementary to GPT's Gyrolab immunoassay systems in applications such as pharmacokinetics studies, detection of anti-drug antibodies, and bioprocess applications. Specifically, the iLite dual reporter gene format allows for normalization of response, eliminating unwanted matrix effects and compensating for differences in cell numbers to achieve accurate and biologically relevant results, the companies noted.
"This agreement with Euro Diagnostica further strengthens the position of Gyros Protein Technologies as a key analytical tools provider focused on developing and supplying drug immunogenicity and biologics solutions that increase productivity for customers in the biopharma and biotech industry," GPT CEO Dan Calvo said in a statement.